print_label | resize_label

Step 1: Identify

Step 1: Identify

Learn how to identify and track who is at high risk for severe RSV disease.


Step 2: Educate Parents

Step 2: Educate Parents

Learn how to educate parents/caregivers about RSV, Synagis (palivizumab), and support programs available to them.


Step 3: Complete Referral

Step 3: Complete Referral

Learn what is needed to efficiently complete a referral.


Step 4: Submit Referral

Step 4: Submit Referral

Learn where, how, and when to send referrals, as well as what you can do to keep the process moving after you hit "submit."


Step 5: Approval or Denial

Step 5: Approval or Denial

Learn how to submit referrals and keep the process moving after you submit.


Step 6: Continuum of Care

Step 6: Continuum of Care

Learn how to ensure Synagis is delivered on time and how Cradle with CareSM can help with patient adherence.


Step 7: iAssist

Step 7: iAssist

Not required for certification.
Learn how to submit and manage referrals from one online location through iAssist.

We’re in your corner

Welcome to Coordinator Corner, designed to educate you about the Synagis® (palivizumab) referral process.

We encourage you to register to become recognized as an official, certified Synagis coordinator and receive an educational resource or an opportunity to make a charitable donation.


Charitable Donation


Educational Textbook

We've made your learning a priority. Each module features:


Informative videos to guide you through the Synagis referral process as well as downloadable scripts and resources to assist in your learning.


Expert Synagis coordinators, available via email, who can assist you with any questions.


A Knowledge Checkpoint for those who want to test their knowledge, become certified, and receive an educational resource or opportunity to make a charitable donation.*

*Those who register and complete all required modules receive certification.


Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (≤35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD). The recommended dose of Synagis is 15 mg/kg of body weight given monthly by intramuscular injection. The first dose of Synagis should be administered prior to commencement of the RSV season and the remaining doses should be administered monthly throughout the RSV season. Children who develop an RSV infection should continue to receive monthly doses throughout the RSV season.

The efficacy of Synagis at doses less than 15 mg/kg, or of dosing less frequently than monthly throughout the RSV season, has not been established.

Synagis is contraindicated in children who have had a previous significant hypersensitivity reaction to Synagis. Cases of anaphylaxis and anaphylactic shock, including fatal cases, have been reported following initial exposure or re-exposure to Synagis. Other acute hypersensitivity reactions, which may be severe, have also been reported on initial exposure or re-exposure to Synagis. The relationship between these reactions and the development of antibodies to Synagis is unknown. If a significant hypersensitivity reaction occurs with Synagis, its use should be permanently discontinued. If a mild hypersensitivity reaction occurs, clinical judgment should be used regarding cautious readministration of Synagis. As with any intramuscular injection, Synagis should be given with caution to children with thrombocytopenia or any coagulation disorder. Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays.

Adverse reactions occurring greater than or equal to 10% and at least 1% more frequently than placebo are fever and rash. In post-marketing reports, cases of severe thrombocytopenia (platelet count <50,000/microliter) and injection site reactions have been reported.

Please see full Prescribing Information for Synagis, including Patient Information.

Frequently asked questions


General Technical Questions

Is the information entered here secure?

Yes. We use the industry standard SSL, to ensure all data is encrypted in transit.

If you have trouble registering for Coordinator Corner, try the following:

  • Ensure all required fields within the form are completed
  • Ensure you are connected to the internet
  • Reach out to your internal IT department to make sure there is not a network problem
  • Once you have explored all options to resolve the matter on your end, contact for technical assistance. A representative will respond to your request within 1 business day.

If you have a problem with streaming video, try the following:

  • Check with your office manager to ensure that your computer does not have a restrictive firewall that prevents you from watching streaming video
  • You can also test if your computer has a restrictive firewall by watching a video from a media site like YouTube. If you are unable to stream a video from YouTube, it is likely that you will not be able to from Coordinator Corner
  • Once you have explored all options to resolve the matter on your end, contact for technical assistance. A representative will respond to your request within 1 business day.

Who can I contact for assistance with any technical issues?

Contact explaining the problem.

Registration Questions

I completed the registration form, but I am unable to submit my information.

Confirm that all mandatory fields have been filled out (this will be denoted with a checkmark) and that the password was entered identically both times.

Will the registration timeout if I take too long to complete?

No, once you start entering information into the form, it will not timeout unless you close your browser.

Will I have access to all content if I do not wish to register?

You will have access to all content and resources; however registration is required to view/complete the Knowledge Checkpoints , to become a Certified Synagis Coordinator and receive an educational resource.

Module Questions

If I don’t watch a video in full the first time, do I need to re-start from the beginning when I come back later?

If you are registered, you will have the capability to resume where you left off, or start from the beginning of the video.

If you are not registered, you will have to restart the video from the beginning.

Can I fast–forward through the video?

If you are registered, you will not be able to advance the video the first time you view it. Once viewed at least one time in full, you will be able to fast–forward through if you like.

If you are not registered, you will be able to advance the video at any time.

I am looking for a support resource, but it is not in any of the modules. Whom should I contact?

If you are looking for a resource that is not associated with any of the modules, please talk to your MedImmune representative for any assistance.

Knowledge Checkpoint Questions

I am clicking on the Knowledge Checkpoint, but the site is not allowing me to access it?

Confirm you have successfully registered and viewed all the required resources associated with that module, then try again.

Once registered, how will I know if I have viewed all the necessary materials in order to access the Knowledge Checkpoint?

All the required materials for a module will be on the module home page menu. Once you view a required resource, the resource icon will be denoted with a green checkmark.

Is there a limit to the number of times I can access a Knowledge Checkpoint?

No, you can take the Knowledge Checkpoint as many times as necessary until you pass.

How do I become eligible to become a Certified Synagis Coordinator and receive the educational resource?

You must first register, then view all necessary videos and resources associated with each of the 6 modules and pass the Knowledge Checkpoint associated with each module.